Related Experiment Video
Updated: Jun 14, 2025
An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
Post-treatment adverse events ranking in targeted immunotherapy for hepatocellular carcinoma: A network meta-analysis
Gaoyuan Yang1, Yupeng Ren1, Yuxuan Li1
1Department of Hepatobiliary Surgery, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou 510630, China.
Background:
Despite the rapid evolution of targeted and immunotherapies for hepatocellular carcinoma (HCC), a systematic comparison of their adverse event profiles remains limited. This review addresses this critical gap by synthesizing data from 13 randomized controlled trials (RCTs) to prioritize treatment regimens on the basis of safety, thereby guiding clinical decision-making in an era of expanding therapeutic options.
Methods:
Clinical studies focusing on targeted and immunotherapies in HCC patients were chosen from databases such as PubMed, Embase, Web of Science and the Cochrane Library, which spans from 2008 to 2023. Data processing and evaluation followed PRISMA guidelines, with a random-effects model employed to merge the data. Network models were then developed, with adverse events serving as the primary endpoint for analysis.
Results:
A comprehensive review of the relevant literature was conducted, identifying 13 randomized controlled trials (RCTs) encompassing 13 treatment protocols for HCC. This study included a total of 10,760 patients. Adverse events within the same category were initially consolidated, followed by the sequential construction of a network model to assess the risk probabilities associated with different targeted immunotherapy regimens for various adverse events and establish priority rankings.
Conclusions:
Cabozantinib, camrelizumab, and their combination therapy for HCC are associated with a higher incidence of common adverse reactions, whereas durvalumab, lenvatinib, and their combination therapy are less likely to cause common adverse effects.
Insights
Cabozantinib and camrelizumab therapies for hepatocellular carcinoma (HCC) show higher adverse events. Durvalumab and lenvatinib therapies for HCC are associated with fewer common adverse effects, aiding treatment decisions.
Area of Science:
- Hepatobiliary Cancers
- Medical Oncology
- Pharmacovigilance
Background:
- Targeted and immunotherapies are rapidly evolving for hepatocellular carcinoma (HCC).
- Limited systematic comparisons of adverse event profiles exist for these HCC treatments.
- This review prioritizes HCC treatment safety based on adverse event data.
Purpose of the Study:
- To systematically compare adverse event profiles of targeted and immunotherapies for HCC.
- To guide clinical decision-making by prioritizing HCC treatment regimens based on safety.
- To synthesize data from randomized controlled trials (RCTs) on HCC treatment safety.
Main Methods:
- Systematic review and meta-analysis of 13 RCTs (2008-2023) on HCC targeted and immunotherapies.
- Data sourced from PubMed, Embase, Web of Science, and Cochrane Library, adhering to PRISMA guidelines.
- Network meta-analysis used to assess adverse events as the primary endpoint and rank treatment risks.
Main Results:
- 13 RCTs involving 10,760 patients and 13 treatment protocols for HCC were analyzed.
- Adverse events were consolidated, and network models were constructed to assess risk probabilities.
- Priority rankings for targeted immunotherapy regimens were established based on various adverse events.
Conclusions:
- Cabozantinib, camrelizumab, and their combination therapy for HCC are linked to a higher incidence of common adverse reactions.
- Durvalumab, lenvatinib, and their combination therapy for HCC are associated with a lower likelihood of common adverse effects.
- Findings aid in selecting safer HCC treatment options.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:27Tumor Immunotherapy